Orally administrated PYDG promotes HBV DNA clearance without causing liver inflammation in the HBV mouse model.

<p>HBV-HDI mice were treated orally with PBS or with 200μg PYDG in 200μl PBS (n = 10) daily for 9 weeks. (A) HBV DNA was monitored weekly. (B) Percentage of HBV DNA positive mice over 9 weeks. (C) HBcAg positive hepatocytes were visualized by immunohistochemistry using anti-HBcAg-HRP, arrows indicate HBcAg. (D) The level of HBsAb was measured in the plasma of mice every 2 weeks. (E) ALT and AST levels in plasma of HDI-HBV mice treated with PYDG or PBS were determined over 9 weeks (*, p<0.05; **, p<0.01; ***, p<0.001).